by Samy Sriram
Share

Payday

Tariff refunds, earnings season and a volatile market. Payoff hinges on turning short-term gains into lasting momentum.

If you inverted Nike’s ($NKE) swoosh logo, you’d get something far less iconic with an uncanny resemblance to the stock’s 5-year price chart. A billion-dollar payday might help it along.

On Monday, the portal for U.S. retailers to claim tariff refunds went live, after the U.S. Supreme Court ruled the levies illegal. Nike could receive US$1B, according to Citigroup – modest next to Walmart’s ($WMT) estimated US$10.2B haul, with total payouts expected to top US$160B.

That’s real cash. Refunds could be used to fund buybacks, pay down debt, or flow straight into earnings down the line. But for now, investor focus is on whether the ongoing earnings season will pay off. This week, around 20% of the S&P 500 reports, including Intel ($INTC) and Tesla ($TSLA).

For Elon Musk, the stakes go well beyond a single quarter. His compensation is tied to some of the most ambitious targets in corporate history: one million robotaxis, 20 million vehicles and a US$8.5T Tesla valuation. Hit them, and his payday could reach US$1T.

At Apple ($AAPL), pay has already been front and centre. Tim Cook took home US$74.6M last year, mostly in stock. Cook took Apple’s market cap from US$350B to US$4T in his 15-year tenure. Now, with hardware chief John Ternus set to take over as CEO, the focus shifts to whether Apple can convert its US$400B revenue machine into an AI leader.

The AI world is well-acquainted with outsized paychecks. And of course, the circular funding playbook. Anthropic struck a massive deal with Amazon ($AMZN) this week, where the latter has agreed to invest up to US$25B in the Claude creator. In turn, Anthropic has agreed to spend over US$100B on Amazon’s chips over the next decade. 

Amazon’s push into healthcare is creating its own ripple effects. The company is expanding into a GLP-1 program, offering popular weight-loss drugs through Amazon Pharmacy for as low as US$25. That move knocked shares of telehealth firm Hims & Hers ($HIMS) down 4% in Tuesday’s session – a reminder that one company’s windfall can be another’s setback.

For investors, the next payday might take a little longer to arrive. After the S&P 500 hit fresh records last week, volatility made a quick return with geopolitical uncertainty. 

Timing the market is a great skill to have. But in this environment, waiting it out might have the better payoff. 

This is not financial advice nor a recommendation to invest in the securities listed. The information presented is for general information purposes only and intended to be of a factual nature only. Past performance is not a reliable indicator of future performance. The author of this article and other employees of Stakeshop Pty Ltd may hold positions or have financial interests in the company (or companies) discussed above. As always, do your own research and consider seeking financial, legal and taxation advice before investing.


Portrait photo of Samy Sriram, Markets Analyst at Stake.

Samy Sriram

Markets Analyst

Samy is a markets analyst at Stake, with seven years of experience in the world of investing, working across roles in private banking, venture capital and financial media. She has a Master’s degree in Finance and Data Analytics from The University of Sydney Business School.


Related


Want more?

You know what to do

Insights, trends and company deep dives delivered straight to your inbox.


Stake logo
Over 12,000 5-star reviews
App Store logoGoogle Play logo

Subscribe to our free newsletters

By subscribing, you agree to our Privacy Policy.

Stakeshop Pty Ltd, trading as Stake, ACN 610 105 505, is an authorised representative (Authorised Representative No. 1241398) of Stakeshop AFSL Pty Ltd (Australian Financial Services Licence no. 548196). Stake SMSF Pty Ltd ACN 648 283 532 (‘Stake Super’) is not licensed to provide financial product advice under the Corporations Act. This specifically applies to any financial products which are established if you instruct Stake Super to set up a self managed super fund (‘SMSF’). When you sign up to Stake Super, you are contracting with Stake SMSF Pty Ltd who will assist in the establishment of a SMSF under a ‘no advice model’. You will also be referred to Stakeshop Pty Ltd to enable your trading account and bank account to be set up in order to use the Stake Website and/or App. For more information about SMSFs, see our SMSF Risks page. The Stake Accumulate Fund (ARSN 680 653 374) is issued by K2 Asset Management Ltd (ABN 95 085 445 094 AFSL 244 393), a wholly owned subsidiary of K2 Asset Management Holdings Ltd (ABN 59 124 636 782). The information on our website or our mobile application is not intended to be an inducement, offer or solicitation to anyone in any jurisdiction in which Stake is not regulated or able to market its services. At Stake and Stake Super, we’re focused on giving you a better investing experience but we don’t take into account your personal objectives, circumstances or financial needs. Any advice given by Stake is of a general nature only. As investments carry risk, before making any investment decision, please consider if it’s right for you and seek appropriate taxation and legal advice. Please view our Financial Services GuideTerms & ConditionsPrivacy Policy and Disclaimers before deciding to invest on or use Stake or Stake Super. By using our website or service in any way, you agree to our Privacy Policy and Terms & Conditions. All financial products involve risk and you should ensure you understand the risks involved as certain financial products may not be suitable to everyone. Past performance of any product described on this website is not a reliable indication of future performance. Stake and Stake Super are registered trademarks in Australia.

Copyright © 2026 Stake. All rights reserved.